HCPCS Level II drug code
J2353 — Injection, octreotide, depot form for intramuscular injection, 1 mg
In short
J2353 is the HCPCS Level II code for injection, octreotide, depot form for intramuscular injection, 1 mg. CMS assigns NDCs for Octreotide Acetate and Sandostatin Lar Depot to it. One billing unit is 1 mg. The Medicare Part B payment limit is $211.321 per unit (October 1, 2026 through December 31, 2026).
Code
CMS HCPCS file- Descriptor
- Injection, octreotide, depot form for intramuscular injection, 1 mg
- Short descriptor
- Octreotide injection, depot
- Code set
- HCPCS Level II, maintained by CMS
- Effective
- Jan 1, 2004
The billing unit is read from the descriptor. Confirm it against the CMS file before billing.
Medicare Part B payment limit
CMS ASP fileEffective October 1, 2026 through December 31, 2026. Payment allowance limits subject to the ASP methodology are based on 2Q26 ASP data. A payment limit is not a coverage decision; the Medicare contractor decides coverage. CMS ASP pricing files
Units and claim line
Units = dose given ÷ 1 mg. For example, 100 mg is 100 units. Enter the dose to get the units and the NDC line for the CMS-1500 and the 837P.
Enter the dose given to build the claim line.
NDCs billed under J2353
CMS’s ASP NDC–HCPCS crosswalk (effective October 1, 2026 through December 31, 2026) assigns 9 NDCs to J2353 for Octreotide Acetate and Sandostatin Lar Depot. Billing units per package are CMS’s figures for this code’s unit.
| Drug | NDC (11-digit) | Labeler | Package | Billing units per package |
|---|---|---|---|---|
| Octreotide Acetate | 00480-9257-08 | Teva Pharmaceuticals USA, Inc. | 1 | 10 |
| Octreotide Acetate | 00480-9259-08 | Teva Pharmaceuticals USA, Inc. | 1 | 20 |
| Octreotide Acetate | 00480-9262-08 | Teva Pharmaceuticals USA, Inc. | 1 | 30 |
| Octreotide Acetate | 67457-0756-10 | Mylan Institutional LLC | 1 | 10 |
| Octreotide Acetate | 67457-0759-20 | Mylan Institutional LLC | 1 | 20 |
| Octreotide Acetate | 67457-0762-30 | Mylan Institutional LLC | 1 | 30 |
| Sandostatin Lar Depot | 00078-0811-81 | Novartis Pharmaceuticals Corporation | 1 | 10 |
| Sandostatin Lar Depot | 00078-0818-81 | Novartis Pharmaceuticals Corporation | 1 | 20 |
| Sandostatin Lar Depot | 00078-0825-81 | Novartis Pharmaceuticals Corporation | 1 | 30 |
J2353: common questions
- Is J2353 a CPT code?
- No. J2353 is a HCPCS Level II code, maintained by CMS, that identifies the drug supplied. CPT codes are five-digit numbers from the AMA that describe services. Giving the drug, for example an injection or infusion, is usually reported with a separate CPT administration code. CPT codes for drug administration.
- What NDCs are billed under J2353?
- CMS's ASP crosswalk for October 1, 2026 through December 31, 2026 lists 9 NDCs under J2353, for Octreotide Acetate and Sandostatin Lar Depot. The table on this page shows each one with its billing units per package.
- What is the Medicare payment limit for J2353?
- $211.321 per 1 mg, effective October 1, 2026 through December 31, 2026, from CMS's Part B drug payment limit file. Multiply by the units billed for the allowed amount before deductible and coinsurance. It is not a coverage decision.
- What is one billing unit of J2353?
- One unit of J2353 is 1 mg, as stated in the code's descriptor. Units to report = dose given ÷ 1 mg. J-code billing units.